Literature DB >> 10998528

Orphanin FQ/nociceptin receptor binding studies.

C T Dooley1, R A Houghten.   

Abstract

A review of the binding studies performed on the receptor (ORL) for Orphanin FQ/Nociceptin is presented. Binding studies have been conducted using a variety of receptor sources: cell lines expressing the cloned receptor, cell lines endogenously expressing the receptor, and brain and other tissue from several different species. Binding studies of opioids, new ligands and antagonists at the ORL receptor are briefly discussed. Saturation, competition and binding kinetic experiments, and the effects of buffer composition are reviewed. There are numerous instances of conflicting data in published reports on OFQ; the basis for these disparities is as yet undetermined. This review endeavors to compile the results and conditions employed in binding studies as an aid to current and new researchers in this field. In an attempt to explain binding disparities, we have determined that Orphanin/Nociceptin binds to glass fiber filtermats in a "specific" manner; these new data are presented.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10998528     DOI: 10.1016/s0196-9781(00)00231-x

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  8 in total

1.  Differential activation of G-proteins by mu-opioid receptor agonists.

Authors:  Zuzana Saidak; Katherine Blake-Palmer; Debbie L Hay; John K Northup; Michelle Glass
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

2.  Binding of the novel radioligand [(3)H]UFP-101 to recombinant human and native rat nociceptin/orphanin FQ receptors.

Authors:  Massimo Ibba; Masato Kitayama; John McDonald; Girolamo Calo; Remo Guerrini; Judit Farkas; Geza Toth; David G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-09-21       Impact factor: 3.000

3.  Nociceptin produces antinociception after spinal administration in amphibians.

Authors:  Craig W Stevens; Kristin K Martin; Brad W Stahlheber
Journal:  Pharmacol Biochem Behav       Date:  2008-09-05       Impact factor: 3.533

4.  Pharmacological studies on the NOP and opioid receptor agonist PWT2-[Dmt1]N/OFQ(1-13).

Authors:  Maria Camilla Cerlesi; Huiping Ding; Mark F Bird; Norikazu Kiguchi; Federica Ferrari; Davide Malfacini; Anna Rizzi; Chiara Ruzza; David G Lambert; Mei-Chuan Ko; Girolamo Calo; Remo Guerrini
Journal:  Eur J Pharmacol       Date:  2016-11-19       Impact factor: 4.432

5.  Modulation of silent and constitutively active nociceptin/orphanin FQ receptors by potent receptor antagonists and Na+ ions in rat sympathetic neurons.

Authors:  Saifeldin Mahmoud; Wojciech Margas; Claudio Trapella; Girolamo Caló; Victor Ruiz-Velasco
Journal:  Mol Pharmacol       Date:  2010-02-16       Impact factor: 4.436

6.  Pharmacological profile of the cyclic nociceptin/orphanin FQ analogues c[Cys10,14]N/OFQ(1-14)NH2 and c[Nphe1,Cys10,14]N/OFQ(1-14)NH2.

Authors:  M Kitayama; T A Barnes; G Carra; J McDonald; G Calo; R Guerrini; D J Rowbotham; G Smith; D G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-04       Impact factor: 3.000

7.  Novel Synthesis and Pharmacological Characterization of NOP Receptor Agonist 8-[(1S,3aS)-2,3,3a,4,5,6-Hexahydro-1H-phenalen-1-yl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (Ro 64-6198).

Authors:  Steven D Chang; Lawrence E Brieaddy; Joseph D Harvey; Anita H Lewin; S Wayne Mascarella; Herbert H Seltzman; P Anantha Reddy; Ann M Decker; Charles J McElhinny; Desong Zhong; Elisha E Peterson; Hernán A Navarro; Michael R Bruchas; F Ivy Carroll
Journal:  ACS Chem Neurosci       Date:  2015-09-30       Impact factor: 4.418

8.  The nociceptin/orphanin FQ receptor system as a target to alleviate cancer-induced bone pain in rats: Model validation and pharmacological evaluation.

Authors:  Sonny H J Sliepen; Johanna Korioth; Thomas Christoph; Thomas M Tzschentke; Marta Diaz-delCastillo; Anne-Marie Heegaard; Kris Rutten
Journal:  Br J Pharmacol       Date:  2020-01-21       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.